Nanoparticle-Based Drug Delivery Systems in Inhaled Therapy: Improving Respiratory Medicine

Pharmaceuticals, Год журнала: 2024, Номер 17(8), С. 1059 - 1059

Опубликована: Авг. 12, 2024

Inhaled nanoparticle (NP) therapy poses intricate challenges in clinical and pharmacodynamic realms. Recent strides have revolutionized NP technology by enabling the incorporation of diverse molecules, thus circumventing systemic clearance mechanisms enhancing drug effectiveness while mitigating side effects. Despite established success delivery oncology other disciplines, exploration inhaled therapies remains relatively nascent. NPs loaded with bronchodilators or anti-inflammatory agents exhibit promising potential for precise distribution throughout bronchial tree, offering targeted treatment respiratory diseases. This article conducts a comprehensive review applications medicine, highlighting their merits, ranging from heightened stability to exacting lung-specific delivery. It also explores cutting-edge technologies optimizing NP-loaded aerosol systems, complemented insights gleaned trials. Furthermore, examines current future prospects NP-based therapies. By synthesizing data perspectives, underscores transformative promise NP-mediated addressing chronic conditions such as obstructive pulmonary disease, pressing global health concern ranked third mortality rates. overview illuminates evolving landscape inhalation therapies, presenting optimistic avenues advancing medicine improving patient outcomes.

Язык: Английский

---

Pulmonary drug delivery devices and nanosystems as potential treatment strategies for acute respiratory distress syndrome (ARDS)

International Journal of Pharmaceutics, Год журнала: 2024, Номер 657, С. 124182 - 124182

Опубликована: Апрель 30, 2024

Язык: Английский

---

The (re)emergence of aerosol delivery: Treatment of pulmonary diseases and its clinical challenges

Journal of Controlled Release, Год журнала: 2025, Номер 379, С. 421 - 439

Опубликована: Янв. 16, 2025

Aerosol delivery represents a rapid and non-invasive way to directly reach the lungs while escaping hepatic first-pass effect. The development of pulmonary drugs for respiratory diseases such as cystic fibrosis, lung infections, fibrosis or cancer requires an enhanced understanding relationships between natural physiology system pathophysiology these conditions. This knowledge is crucial better predict thereby control drug deposition. Moreover, aerosol administration faces several challenges, including tract, immune system, mucociliary clearance, presence fluid on airway surfaces, and, in some cases, bacterial colonisation. Each them influences bioavailability active molecule. In addition particle size device used administer treatment are critical factors that can significantly impact biodistribution drugs. Nanoparticles very promising new formulations delivery, they be fine-tuned entire tract overcome difficulties encountered along way. However, properly assess preclinical studies need more thorough efficiently enhance delivery.

Язык: Английский

---

Development and Evaluation of Aloperine-Loaded Nanostructured Lipid Carriers for the Treatment of Pulmonary Arterial Hypertension

International Journal of Nanomedicine, Год журнала: 2025, Номер Volume 20, С. 871 - 886

Опубликована: Янв. 1, 2025

This study focuses on the development and evaluation of nanostructured lipid carriers (NLCs) loaded with aloperine as a potential therapeutic approach for treatment pulmonary arterial hypertension. The NLCs were designed to enhance solubility, stability, bioavailability aloperine, compound vasodilatory anti-inflammatory properties. Through series experiments including single-factor experimentation, transmission electron microscopy, high-performance liquid chromatography, in vivo pharmacokinetics, tissue distribution studies, we assessed physicochemical properties, drug release profiles, vitro performance this novel nanocarrier. prepared aloperine-loaded exhibited milky white translucent suspension appearance, presenting quasi-spherical shape under microscope, an average particle size (509.48±30.04) nm entrapment efficiency (64.18±1.14)%. profile demonstrated good sustained-release characteristics vitro, formulation remained stable up 15 days when stored at 4°C. Compared solution group, t1/2, AUC(0→t), AUC(0→∞), MRT(0→t), clearance rate 2.3, 2.96, 3.06, 3.03, 0.22 times higher, respectively. indicates that formulating into can prolong its circulation time body. Furthermore, concentrations lungs group 1.79, 3.78, 2.30 higher than those three points (0.25 h, 1.5 4 h), suggesting increase accumulation lungs. Our findings suggest could offer promising strategy

Язык: Английский

---

Nanotechnology-Based Therapeutics for Airway Inflammatory Diseases

Clinical Reviews in Allergy & Immunology, Год журнала: 2025, Номер 68(1)

Опубликована: Фев. 10, 2025

Under the concept of "one airway, one disease", upper and lower airway inflammatory diseases share similar pathogenic mechanisms are collectively referred to as diseases. With industrial development environmental changes, incidence these has gradually increased. Traditional treatments, including glucocorticoids, antihistamines, bronchodilators, have alleviated much discomfort experienced by patients. However, conventional drug delivery routes inherent flaws, such significant side effects, irritation respiratory mucosa, issues related deactivation. In recent years, nanomaterials emerged excellent carriers for being increasingly utilized in treatment These materials not only optimize traditional medications but also facilitate administration various new drugs that target novel pathways, thereby enhancing outcomes This study reviews latest research on nano-drug systems used diseases, covering drugs, immunotherapy antimicrobial plant-derived RNA drugs. The challenges involved developing nano-delivery discussed, along with a future outlook. review offers insights researchers can utilize advance further into clinical application treating

Язык: Английский

---

Impact of nebulizers on nanoparticles-based gene delivery efficiency: in vitro and in vivo comparison of jet and mesh nebulizers using branched-polyethyleneimine

Drug Delivery, Год журнала: 2025, Номер 32(1)

Опубликована: Фев. 10, 2025

Nanoparticles-based gene delivery has emerged as a promising approach for the treatment of genetic diseases based on efficient systems therapeutic nucleic acids (NAs) into target cells. For pulmonary such cystic fibrosis (CF), chronic obstructive (COPD), infectious disease or lung cancer, aerosol is best choice to locally deliver NAs lungs. It is, therefore, important investigate effects nebulization conditions efficiency delivery. To this purpose, non-viral vector branched polyethyleneimine (b-PEI, 25 kDa) was investigated plasmid by aerosol. Two types nebulizers, jet nebulizer and mesh nebulizer, were compared regarding properties nanoparticles (NPs) formed, in vitro vivo models deposition. The results indicate that better performance than application. This superiority demonstrated terms size, concentration, distribution NPs However, deposition appears be similar regardless used, difference between two lies inhalable dose. These underline crucial role techniques optimizing aerosol-mediated b-PEI highlight potential nebulizers tools improved therapy. Therefore, comparison must performed each therapy formulation determine most suitable nebulizer.

Язык: Английский

---

Physicochemical stability of lipid based nanocarriers in aerosol formulation

Elsevier eBooks, Год журнала: 2025, Номер unknown, С. 353 - 369

Опубликована: Янв. 1, 2025

Язык: Английский

---

Effects of Surface Charge of Inhaled Liposomes on Drug Efficacy and Biocompatibility

Pharmaceutics, Год журнала: 2025, Номер 17(3), С. 329 - 329

Опубликована: Март 3, 2025

Objectives: Liposomes are a promising drug carrier for inhaled delivery systems and their physical parameters could influence therapeutic efficacy significantly. This study was designed to answer the specific question of proper surface charge liposomes in pulmonary inhalation, as well synergistic anti-inflammation between drugs. Methods: In this work, series drug-loaded with different charges (from negative positive) were prepared, several vitro vivo assays, including cytotoxicity, hemolysis assay, mucus penetration lipopolysaccharide (LPS)-induced pneumonia model test, adopted evaluate biocompatibility above liposomes. Results: Compared cationic liposomes, anionic capable better good (low blood compatibility mild tissue inflammation), but poor cellular uptake by immune cells. specific, even when liposome only +2.6 mV, its cytotoxicity reached around 20% 15%, respectively. Furthermore, there no significant difference (−25.9 vs. −2.5 mV), slightly negative-charged exhibited uptake. Conclusions: Thus, (−1~−3 mV) be considering both biocompatibility. an LPS-induced mouse model, achieved anti-inflammatory compared free

Язык: Английский

---

Extracellular vesicles-based vaccines: Emerging immunotherapies against cancer

Journal of Controlled Release, Год журнала: 2024, Номер 378, С. 438 - 459

Опубликована: Дек. 21, 2024

Cancer vaccines are promising therapeutic approaches to enhance specific T-cell immunity against most solid tumors. By stimulating anti-tumor immunity, clearing minimal residual disease, and minimizing adverse effects, these target tumor cells effective when combined with immune checkpoint blockade or other immunotherapies. However, the development of cell-based faces quality issues due poor immunogenicity, heterogeneity, a suppressive microenvironment, ineffective delivery methods. In contrast, extracellular vesicles (EVs), naturally released by cells, considered ideal drug carriers vaccine platforms. EVs offer highly organ-specific targeting, induce broader more responses, demonstrate superior tissue ability. The EV is crucial for advancing cancer immunotherapy. Compared vaccines, produced under Good Manufacturing Practices (GMP) advantages such as high safety, ease preservation transport, wide range sources. This review summarizes latest research findings on potential applications in this field. It also highlights novel neoantigens cancer.

Язык: Английский

---

Ferulic Acid: A Comprehensive Review

Cureus, Год журнала: 2024, Номер unknown

Опубликована: Авг. 28, 2024

Ferulic acid (FA), a phenolic compound abundant in the cell walls of seeds, leaves, and roots various fruits, vegetables, cereals, grains, is renowned for its wide range biological activities, including antioxidant, anti-inflammatory, antimicrobial, anticancer properties. Despite therapeutic potential, clinical application FA hindered by challenges such as poor water solubility, limited bioavailability, rapid metabolism, instability under physiological conditions. To address these issues, nanotechnology has emerged transformative approach, enhancing FA's pharmacokinetic profile. Various nanoparticle-based systems, polymer-based lipid-based nanoparticles, have been developed to encapsulate FA. These systems demonstrated significant improvements stability, with studies showing enhanced antioxidant activity controlled release profiles. Further, surface engineering nanoparticles provides targeted drug/phytochemical delivery potential. The drugs/phytochemicals significantly enhances efficacy minimizes systemic side effects. This review explores potential FA, limitations application, advancements that are paving way effective use.

Язык: Английский

---